Medico — Maj 2024
-
GN Store Nord: Bedre end ventet bygger videre på turnaround case https://www.proinvestor.com/boards/120239
-
GN fastholder forventningerne efter solid årsstart https://www.proinvestor.com/investornyt/1153573/gn-fastholder-forventningerne-efter-solid-arsstart
-
Positive overraskelser af GN på alle hovedposter i regnskab https://www.proinvestor.com/investornyt/1153572/positive-overraskelser-af-gn-pa-alle-hovedposter-i-regnskab
-
Kort video: Regnskaber fra Novo, GN Store Nord, Vestas, Mærsk, Pandora - Hvem overrasker? Og hvordan tager markedet imod selskabernes performance i Q1? Helge Larsen kommenterer på regnskaber fra nogle af de helt store selskaber. Hvem skuffer? https://www.proinvestor.com/boards/120260
-
GN's kursmål løftet 9 pct. hos norsk finanshus. https://www.proinvestor.com/investornyt/1154368/gns-kursmal-loftet-9-pct-hos-norsk-finanshus
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://www.proinvestor.com/investornyt/1154378/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
Dagens aktie er Medtronic
Medtronic er af de største virksomheder inden for medicinsk udstyr.
Man udvikler og producerer terapeutisk medicinsk udstyr til kroniske sygdomme. https://www.proinvestor.com/boards/120266/ -
Nordea gentager køb af GN og hæver til 250. "We are encouraged to see broad-based growth as well as massive profitability
and cash flow improvements during Q1, underpinning that GN's "One Company"
transformation is on track. All eyes are now on the Capital Markets Day (7 May),
where we expect the company to present new medium-term targets and an
update on the capital plan. The strong Q1 results increase confidence in the
relatively new management's ability to deliver a successful turnaround of -
f the
business. Therefore, we think it should be a positive trigger if management sets
realistic targets that investors can opt into while staying ambitious enough to
match the sell-side consensus. We maintain Buy and lift our DCF- and multiplebased target price to DKK 250 (220)." -
Novonesis-finansdirektør ser selskabet nå i land med 2024-mål trods blød start https://www.proinvestor.com/investornyt/1154404/novonesis-finansdirektor-ser-selskabet-na-i-land-med-2024-mal-trods-blod-start
-
Norsk finanshus løfter kursmålet for Novonesis https://www.proinvestor.com/investornyt/1155295/norsk-finanshus-lofter-kursmalet-for-novonesis
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://www.proinvestor.com/investornyt/1155298/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
SEB hæver GN's kursmål med 22 pct. https://www.proinvestor.com/investornyt/1155299/seb-haever-gns-kursmal-med-22-pct
-
Demant fastholder forventningerne efter første kvartal https://www.proinvestor.com/investornyt/1155307/demant-fastholder-forventningerne-efter-forste-kvartal
-
Demant: Tomgangsvækst kan give kursusikkerhed https://www.proinvestor.com/boards/120289
-
Demants vækst skuffer lidt - detailforretning er kommet langsomt ud af starthullerne https://www.proinvestor.com/investornyt/1155310/demants-vaekst-skuffer-lidt-detailforretning-er-kommet-langsomt-ud-af-starthullerne
-
Demants topchef: Både markedet og os selv er kommet lidt langsomt i gang i detail https://www.proinvestor.com/investornyt/1155320/demants-topchef-bade-markedet-og-os-selv-er-kommet-lidt-langsomt-i-gang-i-detail
-
Coloplast Q2: Tabel for regnskabet https://www.proinvestor.com/boards/120301
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind